Business Wire

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Share

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005391/en/

Integrity Bio is known in the biopharmaceutical industry as experts in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the organization formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled its manufacturing capacity. Integrity Bio’s customers range from global Fortune 500 companies to small virtual startups.

Integrity Bio’s biologic capabilities are complementary with Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three center-of-excellence facilities in Albuquerque, New Mexico; Burlington, Massachusetts and Glasgow, Scotland.

“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”

“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”

The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.

About Curia

Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Integrity Bio

Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries. The organization is known for overcoming challenges associated with biologic formulations and for accommodating unique manufacturing requirements for preclinical and clinical development. For more information, please visit IntegrityBio.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ABP Publishing Exceeded 500 Audiobooks in Its Catalogue, and Sales Are Forecasted to Grow 30% in 202129.7.2021 10:30:00 CEST | Press release

ABP Publishing announces its audiobook catalogue exceeded 500 titles. The European publisher go on to say that they are forecasting a 100% increase in titles (1000 titles) by 2024. In addition, a 30% increase in total sales is predicted before the end of 2021, continuing a five-year trend of growth. There are plans to publish 17% more titles in 2022 and continue growing the catalogue to meet their 100% increase target by 2024. To meet these targets, ABP Publishing plans to expand its presence gradually in markets it entered recently, such as Turkey, Japan, Korea, and Spain. Additionally, it will continue to work with local authors, particularly in Germany and France. "For the last three years, ABP Publishing has shown solid growth in sales and production. It means that we managed to create an effective system of acquiring rights to high-potential books and externalizing them into good quality audiobooks. I believe the combination will help us achieve our main aim during the next three

Henley & Partners: Investment Migration: “We Need More, Not Less Immigration of People Who Contribute Positively to Society”29.7.2021 10:00:00 CEST | Press release

Henley & Partners Chairman Dr. Christian H. Kaelin says the significant worldwide expansion of investment migration, by which affluent individuals invest in other countries to acquire residence or citizenship, is simply unstoppable. Speaking at The World Ahead Gala Dinnerhosted by The Economist in Athens last week, Dr. Kaelin stated that all over the world countries have realized the importance of residence and citizenship to attract much-needed foreign direct investment, debt-free capital, talented entrepreneurs, and experienced investors. Dr. Kaelin, who is widely considered the pioneer and one of the world’s foremost experts in investment migration, shared the stage with Ireland’s Minister for Finance and President of the Eurogroup, Paschal Donohoe, and Greece’s Minister of Finance, Christos Staikouras, at the annual event to discuss the year ahead with government and business leaders. Further accelerated by the need to alleviate the financial distress following the Covid-19 pandemi

Katherine Alexakis Appointed to Chief Financial Officer of euNetworks29.7.2021 10:00:00 CEST | Press release

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the appointment of Katherine Alexakis to the leadership team, taking up the role of Chief Financial Officer. This appointment is effective 6 September 2021, at which time Katherine will also join the Board of Directors as an Executive Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005060/en/ Brady Rafuse, CEO of euNetworks (Photo: Business Wire) Katherine joins euNetworks after 15 years working at Goldman Sachs International in London, where she held several roles across the European Equities business. She most recently served as a Managing Director within European Equity Research, sitting on the European Investment Review Committee and leading the European Tactical Research Group. Katherine was also responsible for merchandising the research product across the Securities division. Previously, Katheri

Onera raises €10.5M in Series B funding29.7.2021 10:00:00 CEST | Press release

Onera Health, a leader in sleep diagnostic and monitoring solutions, closed the Series B funding round today, which brought the total funding raised to date above the €24M mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005036/en/ The model is wearing the head and chest patch of Onera STS innovative PSG system. (Photo: Business Wire) Led by Innovation Industries in close collaboration with Invest-NL and with existing investors Jazz Pharmaceuticals, imec.xpand, BOM and 15th Rock, the company intends to use the funds to execute clinical studies and further commercialize its sleep diagnostics and monitoring products in Europe and the United States. Onera has recently obtained the CE mark for its first product, an innovative polysomnography (PSG) system that brings the gold-standard quality of a hospital diagnostic system directly to a user’s home. “We’re going to leverage the funding to conduct progressively larger s

Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology29.7.2021 10:00:00 CEST | Press release

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger will lead the advancement of Prokarium’s oncology pipeline into the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005044/en/ Uz Stammberger, MD, Chief Medical Officer of Prokarium (Photo: Business Wire) “Uz brings extensive clinical experience to Prokarium’s team having spent more than two decades in oncology drug development and research,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “We are thrilled to welcome Uz onboard as we expand our clinical portfolio into oncology, and I look forward to working together on the development of our next generation immuno-oncology pipeline.” “Prokarium’s unique technology based on live, attenuated bacteria is a promising and powerful strategy for

BehavioSec Expands Portfolio and Opens Market Access with Another Industry First29.7.2021 09:00:00 CEST | Press release

BehavioSec, industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced that it has extended its patented technology and BehavioSense platform into a SOC/ISO compliant, hosted-version and a cloud-native, SaaS version. These new versions will help more organizations meet compliance and cloud mandates, support frictionless multi-factor authentication (MFA), and gain access to the market’s most advanced behavioral biometrics technology – which until now – has only been employed within the world’s largest banks, e-Identity providers, and online retailers. According to the recent July release of the 2021 Gartner ® Market Guide for Online Fraud Detection, “The convergence between online fraud detection (OFD), identity proofing and authentication continues with many organizations applying OFD capabilities to mitigate risk in identity proofing and authentication events.” The report further adds, “Banks are becoming increasingly comfortable wi

SES Enters Multi-transponder Agreement with NewSpace India Limited via SES-829.7.2021 08:58:00 CEST | Press release

SES announced today that it had entered into a multi-transponder agreement for its SES-8 satellite with NewSpace India Limited (NSIL), a Central Public Sector Enterprise (CPSE) under Department of Space (DoS) based in Bengaluru, India. The nine-transponder capacity agreement on SES-8 at 95 degrees East will be used to support India’s thriving direct-to-home (DTH) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006179/en/ SES Enters Multi-transponder Agreement with NewSpace India Limited via SES-8 (Photo: Business Wire) Deepak Mathur, Executive Vice President of Sales at SES Video, said, “Satellite TV and the programmes it brings hold a very important role for Indian TV viewers. We are honoured to be able to provide continued support and satellite capacity needed to support DTH operations in the country in collaboration with NSIL." Follow us on: Read our Blogs > Visit the Media Gallery > About SES SES has a bold